These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36820081)

  • 1. Evaluation of Tigecycline Utilization and Trends in Antibacterial Resistance from 2018 to 2021 in a Comprehensive Teaching Hospital in China.
    Zhou H; Sun X; Lyu S; Yu X; Li R; Wang H; An Z
    Infect Drug Resist; 2023; 16():879-889. PubMed ID: 36820081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised Outcome.
    Moghnieh RA; Abdallah DI; Fawaz IA; Hamandi T; Kassem M; El-Rajab N; Jisr T; Mugharbil A; Droubi N; Al Tabah S; Sinno L; Ziade F; Daoud Z; Ibrahim A
    Front Microbiol; 2017; 8():497. PubMed ID: 28396656
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of an antibiotic stewardship program on tigecycline use in a Tertiary Care Hospital, an intervention study.
    Moghnieh R; Abdallah D; Awad L; Jadayel M; Haddad N; Tamim H; Zaiter A; Awwad DC; Sinno L; El-Hassan S; Lakkis R; Khalil R; Jisr T
    Ann Clin Microbiol Antimicrob; 2020 Aug; 19(1):35. PubMed ID: 32762758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.
    Guner R; Hasanoglu I; Keske S; Kalem AK; Tasyaran MA
    Infection; 2011 Dec; 39(6):515-8. PubMed ID: 21789524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii.
    Zhou Y; Chen X; Xu P; Zhu Y; Wang K; Xiang D; Wang F; Banh HL
    BMC Pharmacol Toxicol; 2019 Apr; 20(1):19. PubMed ID: 31023357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline treatment of critically ill patients: the LatinUser experience.
    Curcio D; Vargas SW; Ugarte Ubiergo S; Varón F; Rojas Suarez J; Paz Chávez C; Curiale A;
    Curr Clin Pharmacol; 2011 Feb; 6(1):18-25. PubMed ID: 21235466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China.
    Yu K; Zeng W; Xu Y; Liao W; Xu W; Zhou T; Cao J; Chen L
    Antimicrob Resist Infect Control; 2021 Jan; 10(1):16. PubMed ID: 33461617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
    Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
    PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
    Kuo SC; Wang FD; Fung CP; Chen LY; Chen SJ; Chiang MC; Hsu SF; Liu CY
    J Microbiol Immunol Infect; 2011 Feb; 44(1):45-51. PubMed ID: 21531352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
    Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
    J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection.
    Shin JA; Chang YS; Kim HJ; Kim SK; Chang J; Ahn CM; Byun MK
    Yonsei Med J; 2012 Sep; 53(5):974-84. PubMed ID: 22869481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Off label uses of tigecycline].
    Ben Mabrouk A; Ben Brahim H; Kooli I; Marrakchi W; Aouam A; Loussaief C; Toumi A; Chakroun M
    Ann Pharm Fr; 2021 May; 79(3):244-254. PubMed ID: 33289663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.
    Principe L; D'Arezzo S; Capone A; Petrosillo N; Visca P
    Ann Clin Microbiol Antimicrob; 2009 May; 8():18. PubMed ID: 19460166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.
    Curcio D; Fernández F; Cané A; Barcelona L; Stamboulian D
    Braz J Infect Dis; 2008 Jun; 12(3):198-201. PubMed ID: 18833403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
    Wang Q; Huang M; Zhou S
    J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
    J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline.
    Bhattacharya M; Parakh A; Narang M
    J Postgrad Med; 2009; 55(1):65-8. PubMed ID: 19242083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.